Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer

Ana C. Garrido-Castro, Cristina Saura, Romualdo Barroso-Sousa, Hao Guo, Eva Ciruelos, Begoña Bermejo, Joaquin Gavilá, Violeta Serra, Aleix Prat, Laia Paré, Pamela Céliz, Patricia Villagrasa, Yisheng Li, Jennifer Savoie, Zhan Xu, Carlos L. Arteaga, Ian E. Krop, David B. Solit, Gordon B. Mills, Lewis C. CantleyEric P. Winer, Nancy U. Lin, Jordi Rodon

Communication, School of

Research output: Contribution to journal › Article › peer-review

51 Scopus citations

2 results
- Title
- Start date(ascending)

Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer
Garrido-Castro, A. C. (Creator), Saura, C. (Creator), Barroso-Sousa, R. (Creator), Guo, H. (Creator), Ciruelos, E. (Creator), Bermejo, B. (Creator), Gavilá, J. (Contributor), Serra, V. (Creator), Prat, A. (Contributor), Paré, L. (Creator), Céliz, P. (Creator), Villagrasa, P. (Creator), Li, Y. (Contributor), Savoie, J. (Creator), Xu, Z. (Creator), Arteaga, C. L. (Creator), Krop, I. E. (Creator), Solit, D. B. (Creator), Mills, G. B. (Creator), Cantley, L. C. (Creator), Winer, E. P. (Creator), Lin, N. U. (Creator), Rodon, J. (Creator), Aleix, P. (Contributor), Arteaga, C. L. (Creator), Mills, G. B. (Creator), Cantley, L. C. (Creator) & Winer, E. P. (Creator), figshare, 2020
DOI: 10.6084/m9.figshare.c.5195167, https://springernature.figshare.com/collections/Phase_2_study_of_buparlisib_BKM120_a_pan-class_I_PI3K_inhibitor_in_patients_with_metastatic_triple-negative_breast_cancer/5195167
Dataset
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer
Garrido-Castro, A. C. (Creator), Saura, C. (Creator), Barroso-Sousa, R. (Creator), Guo, H. (Creator), Ciruelos, E. (Creator), Bermejo, B. (Creator), Gavilá, J. (Contributor), Serra, V. (Creator), Prat, A. (Contributor), Paré, L. (Creator), Céliz, P. (Creator), Villagrasa, P. (Creator), Li, Y. (Contributor), Savoie, J. (Creator), Xu, Z. (Creator), Arteaga, C. L. (Creator), Krop, I. E. (Creator), Solit, D. B. (Creator), Mills, G. B. (Creator), Cantley, L. C. (Creator), Winer, E. P. (Creator), Lin, N. U. (Creator), Rodon, J. (Creator), Aleix, P. (Contributor), Arteaga, C. L. (Creator), Mills, G. B. (Creator), Cantley, L. C. (Creator) & Winer, E. P. (Creator), figshare Academic Research System, 2020
DOI: 10.6084/m9.figshare.c.5195167.v1, https://springernature.figshare.com/collections/Phase_2_study_of_buparlisib_BKM120_a_pan-class_I_PI3K_inhibitor_in_patients_with_metastatic_triple-negative_breast_cancer/5195167/1
Dataset

Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer

Datasets

Search results

Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer

Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer